Phase 3Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Sponsored by Bristol-Myers Squibb
About this study
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Enrolling at this location
Alliance Dermatology
Phoenix, Arizona
I'm interestedThis study also enrolls at 130 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.